$172.92
Value $49.0B
A and ABT stock compared: price, dividend, valuation and results, from SEC filings.
$172.92
Value $49.0B
$107.45
Value $187B
Agilent Technologies (A) has a market value of $49.0B and Abbott Laboratories (ABT) $187B. Over the last year, with dividends, A moved +18.6% and ABT -15.7%. The P/E is 34.0 for A and 39.7 for ABT. Dividend yield: A 0.59%, ABT 2.35%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
A$49.0B
ABT$187B
ABT is 3.8 times A
Revenue, 12 months
A$7.4B
ABT$48.2B
ABT is 6.5 times A
Net income, 12 months
A$1.4B
ABT$4.7B
ABT is 3.3 times A
Operating margin
A22.2%
ABT13.8%
8.4 points apart
ROIC
A13.7%
ABT6.3%
7.4 points apart
P/E
A34.0
ABT39.7
ABT is 1.2 times A
Dividend yield
A0.6%
ABT2.4%
1.8 points apart
5-year return
A+13.6%
ABT-8.3%
21.9 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
A+13.6%
ABT-8.3%
| Period | AWith dividends | ABTWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +18.6%Price +17.8% | -15.7%Price -17.7% |
| 3 years since November 16, 2023 | +54.8%+15.7% a yearPrice +51.4% | +14.2%+4.5% a yearPrice +7.2% |
| 5 years since November 15, 2021 | +13.6%+2.6% a yearPrice +9.6% | -8.3%-1.7% a yearPrice -17.0% |
| 10 years since November 16, 2016 | +304.5%+15.0% a yearPrice +274.4% | +224.5%+12.5% a yearPrice +169.0% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
AAgilent TechnologiesABTAbbott Laboratories
| Price | $172.92 | $107.45 |
|---|---|---|
| Market value | $49.0B | $187B |
| Enterprise value (EV) | $51.2B | $214B |
| P/E | 34.0 | 39.7 |
| P/E, 5-year median | 32.0 | 33.7 |
| P/B | 6.7 | 3.7 |
| EV/EBIT | 31.3 | 32.1 |
| Free cash flow yield | 2.6% | 3.6% |
| Revenue, 12 months | $7.4B | $48.2B |
|---|---|---|
| Net income, 12 months | $1.4B | $4.7B |
| Free cash flow, 12 months | $1.3B | $6.8B |
| Earnings per share, 12 months | $5.07 | $2.69 |
| Revenue growth, year on year | 6.7% | 5.7% |
| Revenue growth a year, past | +5.4%over 5 years | +5.1%over 5 years |
| EPS growth a year, past | +14.7%over 5 years | +8.3%over 5 years |
| Gross margin | 53.8% | 56.9% |
|---|---|---|
| Operating margin | 22.2% | 13.8% |
| Net margin | 19.5% | 9.8% |
| ROIC | 13.7% | 6.3% |
| ROE | 20.9% | 9.1% |
| Cash | $1.8B | $4.3B |
|---|---|---|
| Total debt | $4.1B | $31.2B |
| Net debt / EBITDA | 1.1 | 3.3 |
| Interest cover | 15.5× | 6.7× |
| Dividend yield | 0.6% | 2.4% |
|---|---|---|
| Dividend per share, 12 months | $1.02 | $2.52 |
| Dividend growth a year, past | +6.6%over 5 years | +10.4%over 5 years |
| Buyback yield | 0.9% | 0.5% |
| Shareholder yield | 1.5% | 2.8% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Abbott Laboratories ($187B) is about 3.8 times Agilent Technologies ($49.0B), at today's prices.
Since November 16, 2016, A's price moved +274.4% and ABT's +169.0%. With dividends: A +304.5% (+15.0% a year), ABT +224.5% (+12.5% a year). Past returns do not predict future ones.
The dividend yield at today's price is 0.59% for Agilent Technologies and 2.35% for Abbott Laboratories. Over the last twelve months they paid $1.02 and $2.52 per share.
At today's price, the P/E is 34.0 for A and 39.7 for ABT. The median of the last five years was 32.0 and 33.7, which shows where each stands against its own past.
Over the last twelve months, the net margin was 19.5% for Agilent Technologies and 9.8% for Abbott Laboratories, and the operating margin 22.2% and 13.8%. Revenue was $7.4B and $48.2B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.